Evidence map›Paper›PMID 38947083›Full record

ArticleResearch square2024

12/15-Lipooxygenase Inhibition Reduces Microvessel Constriction and Microthrombi after Subarachnoid Hemorrhage in Mice.

Ari Dienel, Sung Ha Hong, Hussein A Zeineddine, Sithara Thomas, C M Shafeeque, Dania A Jose, Kiara Torres, Jose Guzman, Andrew Dunn, T P Kumar and 3 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Ari DienelThe Vivian L. Smith, The University of Texas Health Science Center at Houston.
Sung Ha HongThe Vivian L. Smith, The University of Texas Health Science Center at Houston.
Hussein A ZeineddineThe Vivian L. Smith, The University of Texas Health Science Center at Houston.
Sithara ThomasThe Vivian L. Smith, The University of Texas Health Science Center at Houston.
C M ShafeequeThe Vivian L. Smith, The University of Texas Health Science Center at Houston.
Dania A JoseThe Vivian L. Smith, The University of Texas Health Science Center at Houston.
Kiara TorresThe Vivian L. Smith, The University of Texas Health Science Center at Houston.
Jose GuzmanThe Vivian L. Smith, The University of Texas Health Science Center at Houston.
Andrew DunnThe University of Texas at Austin.
T P KumarThe Vivian L. Smith, The University of Texas Health Science Center at Houston.
Gadiparthi N RaoUniversity of Tennessee Health Science Center.
Spiros L BlackburnThe Vivian L. Smith, The University of Texas Health Science Center at Houston.
Devin W McBrideThe Vivian L. Smith, The University of Texas Health Science Center at Houston.

Funding

Role of Microthrombi and Inflammation in Delayed Deficits after SAHR01NS115887 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCBRIDE, DEVIN WILLIAM · 2021 to 2025
$2.7M
NINDS NIH HHS R01 NS115887
6 · The paper itself

Abstract

Background and Purpose: Impaired cerebral circulation, induced by blood vessel constrictions and microthrombi, leads to delayed cerebral ischemia after subarachnoid hemorrhage (SAH). 12/15-Lipooxygenase (12/15-LOX) overexpression has been implicated in worsening early brain injury outcomes following SAH. However, it is unknown if 12/15-LOX is important in delayed pathophysiological events after SAH. Since 12/15-LOX produces metabolites that induce inflammation and vasoconstriction, we hypothesized that 12/15-LOX leads to microvessel constriction and microthrombi formation after SAH, and thus 12/15-LOX is an important target to prevent delayed cerebral ischemia. Methods: SAH was induced in C57BL/6 and 12/15-LOX Results: In SAH mice, 12/15-LOX was upregulated in brain vascular cells and there was an increase in 12-S-HETE. Inhibition of 12/15-LOX improved brain perfusion on days 4-5 and attenuated delayed pathophysiological events, including microvessel constrictions, microthrombi, neuronal degeneration, and infarction. Additionally, 12/15-LOX inhibition reduced platelet activation in human and mouse blood samples. Conclusions: Cerebrovascular 12/15-LOX overexpression plays a major role in brain dysfunction after SAH by triggering microvessel constrictions and microthrombi formation, which reduces brain perfusion. Inhibiting 12/15-LOX may be a therapeutic target to improve outcomes after SAH.

Indexed as

12/15-Lipooxygenasearteriolesdelayed neurological deficitmicrothrombimicrovessel constrictionsplateletssubarachnoid hemorrhage

Identifiers

PMID38947083
PMCPMC11213206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.